CRIS aims to obtain scientific evidence about the application of Cannabinoids and Medical cannabis to humans and animals, for health, disease and disorders.
A strategic management executive committee coordinates activities and develops research opportunities.
[2] The CARE-E clinical trial of a cannabis oil with high cannabidiol content with pediatric patients with refractory epilepsy was a key factor in initiating the research initiative.
[3] The CARE-E trial received extensive media coverage when it was launched.
[4] [5] The therapeutic effect of pure cannabidiol (Epidiolex GW Pharmaceuticals) on Dravet Syndrome was recently reported in the New England Journal of Medicine [6] [7] The CRIS group has expanded to biomedical science studies of the pharmacology of cannabinoids and synthetic cannabinoids.